Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06313853 · ClinicalTrials.gov registry record · NA

Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision

A NA study of Cancer and Dementia, sponsored by University of Rochester.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT06313853: Recruiting NA study of Cancer and Dementia, sponsored by University of Rochester.

NCT06313853 is a NA study of Cancer and Dementia that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 300 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06313853, a NA study of Cancer and Dementia, is actively recruiting participants, sponsored by University of Rochester.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

Building upon prior work, the investigator team developed a communication intervention for older adults with ADRD who are considering a decision about cancer management (adapted intervention: COACH-Cog). The investigators hypothesize that for patients with dual diagnoses of ADRD and cancer, COACH-Cog will increase autonomy support of care partners and patients in the decision-making process, leading to greater acknowledgement and support of cognitive concerns and cognitive-related goals, thereby improving goal concordant care. The investigators are conducting a pilot randomized controlled trial (RCT; cluster randomized by physician) including approximately 45 oncology clinicians and 130 patient/care partner dyads evaluating the effect of COACH-Cog on care partner and patient autonomy support, care partner well-being, goal-concordance, and communication.

Primary Outcome

Care Partner autonomy support; score range: 6-42; higher score is better.

Conditions Studied

Interventions

  • BEHAVIORAL COACH-Cog

Study Locations (1)

New York

  • University of Rochester Wilmot Cancer Institute - Rochester

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-10-01
Est. Completion 2027-04-30
Phase NA
University of Rochester

636 total trials

What NCT06313853 shows while recruiting

NCT06313853 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which COACH-Cog is the first listed.

NCT06313853 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06313853 about?

NCT06313853 is a clinical study titled "Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision". Building upon prior work, the investigator team developed a communication intervention for older adults with ADRD who are considering a decision about cancer management (adapted intervention: COACH-Cog). The investigators hypothesize that for patients with dual diagnoses of ADRD and cancer, COACH-Co...

What is the current status of trial NCT06313853?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-10-01. Estimated completion is 2027-04-30.

What conditions does trial NCT06313853 study?

This clinical trial studies the following conditions: Cancer, Dementia.

What interventions are being tested in trial NCT06313853?

The interventions under investigation include: COACH-Cog (BEHAVIORAL).

Who is sponsoring clinical trial NCT06313853?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06313853 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06313853's enrollment target sits among peer trials

300 179th of 615 higher than 428 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06313853, the US trial registry maintained by the National Library of Medicine. NCT06313853 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.